Tibolone: A compound with tissue specific inhibitory effects on sulfatase

Molecular and Cellular Endocrinology

Volumn 183, Issue 1-2, 2001, Pages 55-62

  De Gooyer, Marcel E ^a   Overklift Vaupel Kleyn, George T ^a   Smits, Karin C ^a   Ederveen, Antwan G H ^a   Verheul, Herman A M ^a   Kloosterboer, Helenius J ^a  

^a NV ORGANON   (Netherlands)

Author keywords

Bone; Breast; Endometrium; Sulfatase inhibition; Tibolone; Tissue specificity

Indexed keywords

DRUG METABOLITE; ENZYME INHIBITOR; ESTRONE DERIVATIVE; ESTRONE SULFATE; SULFATASE; TIBOLONE;

ARTICLE; BONE; BREAST CELL; CELL LINE; CONTROLLED STUDY; ENDOMETRIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; OSTEOBLAST; PRIORITY JOURNAL; TISSUE SPECIFICITY;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST; CELL LINE; ENDOMETRIUM; ENZYME INHIBITORS; ESTRONE; FEMALE; HUMANS; NORPREGNENES; ORGAN SPECIFICITY; OSTEOBLASTS; SULFATASES; TUMOR CELLS, CULTURED;

EID: 18144451220     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(01)00606-2     Document Type: Article

References (29)

1. Characterization, in the guinea pig, of hepatic cytosol protein binding dehydroepiandrosterone sulfate and estrone sulfate
2. A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid
3. Effect of tibolone (Org OD 14) and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells
4. Human estrogen sulfotransferase (hEST1) activities and its mRNA in various breast cancer cell lines. Effect of the progestin, promegestone (R-5020)
5. Effect of Org OD14 (Livial) and its metabolites on human estrogen sulphotransferase activity in hormone-dependent MCF-7 and T-47D, and hormone-independent MDA-MB-231, breast cancer lines
6. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer
7. Tibolone, a steroid with a tissue-specific hormonal profile, completely prevents ovariectomy-induced bone loss in sexually mature rats
8. Steroid metabolizing enzymes associated with the microvillar membrane of human placenta
9. Cancer of the breast: the last decade
10. Constitutive expression of the steroid sulfatase gene supports the growth of MCF-7 human breast cancer cells in vitro and in vivo
11. Tibolone and its metabolites: pharmacology, tissue specificity and effects in animal models of tumors
12. Effects of progestagens and Org OD 14 in in vitro and in vivo tumour models
13. In vitro evaluation of estrogenic, estrogen antagonistic and progestational effects of a steroidal drug (Org OD 14) and its metabolites on human endometrium
14. In situ steroid sulfatase activity in human epithelial carcinoma cells of vaginal, ovarian, and endometrial origen
15. Livial®: a review of clinical studies
16. Estrogen replacement therapy and osteoporosis: principles and practice
17. Role, control and expression of estrone sulfatase and 17β-hydroxysteroid dehydrogenase activities in human breast cancer
18. Estrone sulfate-sulfatase and 17β-hydroxysteroid dehydrogenase activities: a hypothesis for their role in the evolution of human breast cancer from hormone dependence to hormone independence
19. Estrogen synthesis by osteoblast cell lines
20. Regulation of sulphotransferase expression in endometrium during the menstrual cycle, by oral contraceptives and during early pregnancy
21. Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways
22. Hormones and mammary carcinogenesis
23. Molecular biology and genetics of the 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase gene family
24. Human endometrial 3 beta-hydroxysteroid dehydrogenase/isomerase can locally reduce estrogenic/progestagenic activity ratios of a steroidal drug (Org OD 14)
25. Mammographic density in postmenopausal women treated with tibolone, estriol or conventional hormone replacement therapy
26. Endocrinological studies with (7alpha,17alpha)-17-hydroxy-7-methyl-19-norpregn-5 (10)-en-20-yn-3-one (Org OD 14)